ERBB2 and breast carcinoma: Approximately 15–20% of breast cancer patients overexpress the HER2 gene, leading to poor outcomes, making it the most prevalent malignancy in women all over the world (Herceptin, Roche), has been the first-line treatment of early and advanced HER2-positive breast cancer (Fotis et al., 2018; Padrón et al., 2020).